Literature DB >> 6260681

Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis.

J J Munoz, H Arai, R L Cole.   

Abstract

We compared the protective activities of fimbrial hemagglutinin (FHA) and pertussigen and their respective antibodies in mice infected intracerebrally with Bordetella pertussis. We found that mice were protected by a 1.7-microgram/mouse dose of pertussigen which was free of detectable FHA and was detoxified by treatment with glutaraldehyde. A pertussigen preparation made from cells grown in shake cultures that did not contain demonstrable FHA protected mice at a dose of 1.4 microgram/mouse. FHA at a dose of 10 microgram/mouse protected mice from intracerebral infection, but it also sensitized mice to histamine at a dose of 2 micrograms/mouse, which indicated that it was contaminated with pertussigen. When FHA was obtained free of demonstrable pertussigen, it failed to sensitize mice to histamine at a dose of 30 micrograms/mouse and to protect mice from infection at a dose of 12 micrograms/mouse (largest doses tested). Passive protection tests with antisera known to contain antibodies to pertussigen protected mice from intracerebral infection, whereas sera lacking anti-pertussigen antibodies but containing high concentrations of anti-FHA antibodies did not protect mice. The most important antigen for the immunization of mice against intracerebral infection with B. pertussis appears to be pertussigen.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6260681      PMCID: PMC350613          DOI: 10.1128/iai.32.1.243-250.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Biologically active components and properties of Bordetella pertussis.

Authors:  S I Morse
Journal:  Adv Appl Microbiol       Date:  1976       Impact factor: 5.086

2.  Separation and characterization of two distinct hemagglutinins contained in purified leukocytosis-promoting factor from Bordetella pertussis.

Authors:  H Arai; Y Sato
Journal:  Biochim Biophys Acta       Date:  1976-10-22

3.  Islets-activating protein (IAP) in Bordetella pertussis that potentiates insulin secretory responses of rats. Purification and characterization.

Authors:  M Yajima; K Hosoda; Y Kanbayashi; T Nakamura; K Nogimori; Y Mizushima; Y Nakase; M Ui
Journal:  J Biochem       Date:  1978-01       Impact factor: 3.387

4.  Leucocytosis-promoting factor of Bordetella pertussis. I. Purification and characterization.

Authors:  Y Sato; H Arai
Journal:  Infect Immun       Date:  1972-12       Impact factor: 3.441

5.  A simple chemically defined medium for the production of phase I Bordetella pertussis.

Authors:  D W Stainer; M J Scholte
Journal:  J Gen Microbiol       Date:  1970-10

6.  On a possible new kind of toxic substance produced by Bordetella pertussis.

Authors:  M Kurokawa; S Iwasa; S Ishida
Journal:  Jpn J Med Sci Biol       Date:  1965-06

7.  Mouse or man? Which are pertussis vaccines to protect?

Authors:  N W Preston; T N Stanbridge
Journal:  J Hyg (Lond)       Date:  1976-04

8.  Leukocytosis-promoting factor of Bordetella pertussis. II. Biological properties.

Authors:  Y Sato; H Arai; K Suzuki
Journal:  Infect Immun       Date:  1973-06       Impact factor: 3.441

9.  Histamine-sensitizing factor, mouse-protective antigens, and other antigens of some members of the genus Bordetella.

Authors:  R Ross; J Munoz; C Cameron
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

10.  Leukocytosis-promoting factor of Bordetella pertussis. 3. Its identity with protective antigen.

Authors:  Y Sato; H Arai; K Suzuki
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

View more
  46 in total

1.  Characterization of murine monoclonal antibodies that recognize defined epitopes of pertussis toxin and neutralize its toxic effect on Chinese hamster ovary cells.

Authors:  M J Walker; J Wehland; K N Timmis; B Raupach; M A Schmidt
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

2.  Maintenance of biological activity of pertussis toxin radioiodinated while bound to fetuin-agarose.

Authors:  G D Armstrong; M S Peppler
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

3.  Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping.

Authors:  A B Lang; M T Ganss; S J Cryz
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

4.  Antibody-mediated neutralization of pertussis toxin-induced mitogenicity of human peripheral blood mononuclear cells.

Authors:  Scott H Millen; David I Bernstein; Beverly Connelly; Joel I Ward; Swei-Ju Chang; Alison A Weiss
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  A whole-organ perfusion model of Bordetella pertussis adherence to mouse tracheal epithelium.

Authors:  L O Bakaletz; M S Rheins
Journal:  In Vitro Cell Dev Biol       Date:  1985-06

6.  Serum antibody responses to the outer membrane proteins of Bordetella pertussis.

Authors:  K Redhead
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

7.  Identification of B-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  P H Ibsen; A Holm; J W Petersen; C E Olsen; I Heron
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

8.  A phase variant of Bordetella pertussis with a mutation in a new locus involved in the regulation of pertussis toxin and adenylate cyclase toxin expression.

Authors:  N H Carbonetti; N Khelef; N Guiso; R Gross
Journal:  J Bacteriol       Date:  1993-10       Impact factor: 3.490

9.  Protection against experimental Bordetella bronchiseptica infection in mice by active immunization with killed vaccine.

Authors:  K Sekiya; M Kawahira; Y Nakase
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

10.  Immune response to dimeric subunits of the pertussis toxin B oligomer.

Authors:  S Z Hausman; D L Burns; V C Sickler; C R Manclark
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.